Dublin, Feb. 05, 2025 (GLOBE NEWSWIRE) — The “CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035” report has been added to ResearchAndMarkets.com’s offering.
The global CAR T-cell therapy market is estimated to grow from USD 4.6 billion in the current year to USD 15.2 billion by 2035, at a CAGR of 11.4% during the forecast period, till 2035.
CAR T-CELL THERAPY MARKET GROWTH AND TRENDS
Cancer research continues to be one of the most active segments, in terms of drug development, within the pharmaceutical industry. In fact, in the past few years, the USFDA has approved more than 70 drugs for the treatment of different types of cancer. Given the challenges associated with conventional therapies, such as non-specificity, drug developers are actively investigating more targeted anti-cancer therapies. Of these, CAR T-cell therapies have emerged as a promising option. CAR T-cell therapy leverages the body’s own immune system to target and eliminate cancer cells.
CAR-T cell therapies have been demonstrated to enable complete disease remission, omitting the need for additional treatment; several studies have proven the efficacy of these therapy candidates. It is worth highlighting that close to 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, indicating substantial research activity. At present, over 230 companies are engaged in the development of CAR T-cell therapies for the treatment of different oncological, non-oncological and other disorders.
Along with the technological advancements in molecular research, the surge in demand for personalized cancer treatment and increase in the number of clinical trials and multiple therapy approvals are some other considerable factors, aiding the growth of this market. Furthermore, continuous financial support from investors is expected to propel the steady growth for the development of CAR-T cell therapy in the mid to long-term.
CAR T-CELL THERAPY MARKET KEY INSIGHTS
The report delves into the current state of the CAR T-cell therapy market and identifies potential growth opportunities within the industry.
Some key findings from the report include:
- CAR-T cell therapies, with over 1240 preclinical / clinical product candidates, represent one of the most active segments in the pharmaceutical domain.
- Close to 75% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature; notably, CD19 and BCMA have emerged as the most popular target antigens.
- Extensive efforts are underway to improve CAR constructs across successive generations, involving alterations in the scFv region via using different types of gene delivery vectors.
- Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development.
- In the last eight years, over 970 clinical trials have been registered across different geographies for CAR-T cell therapies; extensive efforts are underway to improve successive generations of these therapies.
- 375+ scientists from renowned universities are presently involved in the clinical development of CAR-T cell therapies; these KOLs are primarily based in the US and China.
- The rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain.
- Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested more than USD 32 billion, across 370+ instances.
- More than 11,900 patents related to CAR-T cell therapies have been filed / granted to protect the intellectual property generated within this field.
- In order to efficiently promote these therapies and sustain their position in the CAR-T cell therapies market, drug developers are actively exploring diverse promotional strategies.
- Considering the growing prevalence of cancer, technological developments and ongoing approvals, the market for CAR-T cell therapies is poised to witness a steady growth in the foreseen future.
- With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 10%, during the next decade.
CAR T-CELL THERAPY MARKET: KEY SEGMENTS
Multiple Myeloma is Likely to Dominate the CAR T-Cell Therapy Market During the Forecast Period
- Based on target indication, the market is segmented into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, large B-cell lymphoma, mantle cell lymphoma, multiple myeloma and others. It is worth highlighting that the market for CAR-T therapies designed to treat large B-cell lymphoma is projected to grow at an annual growth rate of 14%, during the forecast period.
CD19 Targeting Therapies is Expected to Capture Largest Share in the CAR T-Cell Therapy Market During the Forecast Period
- Based on target antigen, the market is segmented into CD19, BCMA, CD20, CD19 / CD22 and others. It is worth highlighting that the segment for CD19 is likely to capture more than 65% of the overall market in the coming years. This can be attributed to the success of CD19 targeting therapies, such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel).
Key Players in the CAR T-Cell Therapy Market Profiled in the Report:
- Autolus
- Bluebird Bio
- Bristol Myers Squibb
- Carsgen Therapeutics
- Cellectis, Gilead Sciences
- Innovative Cellular Therapeutics
- Noile-Immune Biotech
- Novartis
- Shanghai GeneChem
- Sinobioway Cell Therapy
- Takara Bio
- Wellington Zhaotai Therapies
KEY QUESTIONS ANSWERED IN THIS REPORT
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What kind of partnership models are commonly adopted by industry stakeholders?
- How many clinical trials are running for CAR-T therapies?
- What are the factors that are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 10% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
Key Topics Covered:
1. PREFACE
2. RESEARCH METHODOLOGY
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of T-cell Immunotherapies
5.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy
6. CAR-T CELL THERAPIES: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. CAR-T Cell Therapies: Market Landscape
6.3. CAR-T Cell Therapies: Overall Developer Landscape
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Popular Target Antigens
7.3. CAR-T Therapies: CAR Construct Analysis
8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
9. KEY OPINION LEADERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
10. COMPANY PROFILES
- Autolus
- Bluebird Bio
- Bristol Myers Squibb
- CARsgen Therapeutics
- Cellectis
- Gilead Sciences
- Innovative Cellular Therapeutics
- Noile-Immune Biotech
- Novartis
- Sinobioway Cell Therapy
- Takara Bio
- Wellington Zhaotai Therapies
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. CAR-T Cell Therapies: Partnerships and Collaborations
12. FUNDING AND INVESTMENTS ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. CAR-T Cell Therapies: Funding and Investment Analysis
13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. CAR-T Cell Therapies: Patent Analysis
13.4. Patent Benchmarking Analysis
13.5. Patent Valuation
13.6. Leading Patents by Number Of Citations
14. CASE STUDY: CELL THERAPY MANUFACTURING
14.1. Chapter Overview
14.2. Overview of Cell Therapy Manufacturing
14.3. Cell Therapy Manufacturing Models
14.4. Scalability of Cell Therapy Manufacturing Processes
14.5. Types of Cell Therapy Manufacturers
14.6. Key Challenges Related to Manufacturing of Cell Therapies
14.7. Key Considerations for Cell Therapy Manufacturing
14.8. Automation of Cell Therapy Manufacturing Process
14.9. Cell Therapy Manufacturing Supply Chain
14.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
14.11. Regulatory Landscape
14.12. Future Perspectives
15. COST PRICE ANALYSIS
15.1. Chapter Overview
15.2. Factors Contributing to the High Price of Cell / Gene Therapies
15.3. Pricing Models for T-cell Immunotherapies
15.4. Reimbursement related Considerations for T-cell Immunotherapies
15.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies
16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
17. GLOBAL CAR-T CELL THERAPY MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global CAR-T Cell Therapy Market, Historical Trends (since 2018) and Future Estimates (till 2035)
17.4. Scenario Analysis
17.5. Key Market Segmentations
18. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. CAR-T Cell Therapies Market: Distribution by Type Target Antigen, Current Year and 2035
19. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. CAR-T Cell Therapies Market: Distribution by Target Indication, Current Year and 2035
20. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, Current Year and 2035
21. CAR-T THERAPY MARKET, SALES FORECAST OF DRUGS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Commercialized CAR-T Cell Therapies: Sales Forecast
- Kymriah (Tisagenlecleucel-T)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (Brexucabtagene Autoleucel)
- Abecma (Idecabtagene Vicleucel / bb211211)
- CARVYKTI (LCAR-B38M CAR-T / JNJ-6821845218 / Ciltacabtagene Autoleucel)
- BREYANZI (Lisocabtagene maraleucel, JCAR017)
- Carteyva (Relmacabtagene autoleucel / JWCAR0219)
- NexCART
- Fucaso (Equecabtagene Autoleucel)
- Inaticabtagene Autoleucel CNCT19 / HY001
- Zevorcabtagene autoleucel (CT053)
21.4. Clinical CAR-T Cell Therapies: Sales Forecast
- CAR-BCMA T cells
- CAR-T-CD19 Cells
- Descartes-08
- Zamtocabtagene Autoleucel (MB-CART21019.1)
- CAR-T ddBCMA
- CRG-02121 cells
- CT041
- ALLO-501A / ALLO-501
- ALLO-605
- Descartes-25
- AUTO1
- AUTO3 (CD19/2121 CAR-T)
- AUTO4 (CD19/2121 CAR-T)
- CD19-CAR-T
- Humanized CD19-CAR-T
- IM19 CAR-T
- CCT301 CAR-T
- CARCIK-CD19
- CD123 CAR-T cells
- BCMA CAR-T
- CD19/CD22-CAR-T
- GC012F (Dual CAR-BCMA- 19)
- CD19/CD210-CART
- CD7 CAR-T
- Anti-FLT3 CAR-T / TAA05
- Anti-ALPP CAR-T Cells
- WU CART 007
- CTX110
- TX2100-TR101
- ALETA-001
- PBCAR0191
22. CAR-T CELL THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. CAR-T Cell Therapies: Leading Players Sales Forecasts
- Gilead Sciences
- Bristol Myers Squibb
- Novartis
- Janssen
- JW Therapeutics
23. PROMOTIONAL ANALYSIS
23.1. Chapter Overview
23.2. Channels Used for Promotional Campaigns
23.3. Summary of Product Website Analysis
23.4. Summary of Patient Support Services and Informative Downloads
- Kymriah: Promotional Analysis
- Yescarta: Promotional Analysis
- Tecartus: Promotional Analysis
- Breyanzi: Promotional Analysis
- Abecma: Promotional Analysis
- Carvykti: Promotional Analysis
24. EXECUTIVE INSIGHTS
- Atara Biotherpeutics
- Glycostem Therapeutics
- Gracell Biotechnologies
- TxCell
- Kite Pharma
- Celyad
- Waisman Biomanufacturing
- Theravectys
- Changhai Hospital
For more information about this report visit https://www.researchandmarkets.com/r/gqmuie
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- CAR T-Cell Therapy Patent
- CAR T-Cell Therapy Pipeline
